Clinical Trials

The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses.

Completed

Phase 1 Study in 12 pediatric patients with recurrent high grade glioma (HGG)
  • Improved overall survival 12.2 months versus 5.6 months for historical trials
  • Dramatic Safety Advantage – No serious adverse events
  • Evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot”
  • Original Article “Oncolytic HSV-1 G207 Immunotherapy for Pediatric High-Grade Glioamas” (Friedman GK) published in New England Journal of Medicine April 10, 2021
  • Phase 1 data presented at American Association of Cancer Research (AACR) conference April 10, 2021 (Friedman GK)

Planned 2021

Phase 2 Clinical Trial of G207 in Children with Recurrent High-Grade Glioma
  • 30 children with recurrent glioma
  • Overall Survival measured against historical controls from prior pediatric HGG studies
  • Safety, immune response, and radiographic responses also will be evaluated

Enrolling

Phase 1 Study of G207 in combination with 5Gy radiation in up to 15 patients with recurrent medulloblastoma and other cerebellar tumors.